These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26001178)

  • 1. Should patients in need be given access to experimental drugs?
    Caplan AL; Bateman-House A
    Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 3. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.
    Mackey TK; Schoenfeld VJ
    BMC Med; 2016 Feb; 14():17. PubMed ID: 26843367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
    Borysowski J; Górski A
    Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
    Bateman-House A; Robertson CT
    JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
    [No Abstract]   [Full Text] [Related]  

  • 11. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
    Chapman CR; Eckman J; Bateman-House AS
    Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expanded Access in The Netherlands: prescribing unregistered medicine].
    Polak TB; Cucchi DGJ; van Rosmalen J
    Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.
    Hoerger M
    Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One Last Shot.
    Berlin J
    Tex Med; 2016 Jul; 112(7):33-8. PubMed ID: 27441422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right-to-Try Investigational Therapies for Incurable Disorders.
    Simmons Z
    Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. PubMed ID: 28968371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
    Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
    PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
    Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
    Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing expanded access and compassionate use programs for experimental drugs.
    Miller JE; Ross JS; Moch KI; Caplan AL
    BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food and Drug Administration responds to pressure for expanded drug access.
    Brower V
    J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
    [No Abstract]   [Full Text] [Related]  

  • 20. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.